Global Transarterial Chemoembolization Market

Transarterial Chemoembolization Market Size, Share, Growth Analysis, By Product(Hospitals, Ambulatory Surgical Centers, Specialty Clinics), By End-User(Strawberry, apple, mango, mixed fruit blends), By Technology(Lipiodol-based TACE, Drug-Eluting Bead TACE Technology), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35I2318 | Region: Global | Published Date: July, 2027
Pages: 219 | Tables: 92 | Figures: 76

Transarterial Chemoembolization Market Competitive Landscape

Transarterial chemoembolization market is competitive, comprising both well-established vendors as well as new entrants that lead to dynamism in this industry. The major players in the market are engaging in strategies like new product development, collaboration, and consolidation to increase their dominance. Significant contributions to the competitive dynamics include established medical technology companies specializing in interventional oncology (development of advanced catheters, microcatheters, etc.) as well as embolic agents and drug-eluting bead technologies.

Top Player’s Company Profiles

  • Boston Scientific Corporation (US)
  • Terumo Corporation (Japan)
  • Cook Medical (US)
  • Cardinal Health (US)
  • Becton, Dickinson and Company (US)
  • Guerbet (France)
  • AngioDynamics, Inc. (US)
  • SIRtex Medical Inc. (Australia)
  • Merit Medical Systems Inc. (US)
  • Varian Medical Systems, Inc. (US)
  • Microvena Therapeutics, Inc. (US)
  • RadioMed LLC (US)
  • IGT Laboratories (US)
  • MicroCath, Inc. (US)
  • Spectranetics, Inc. (US)
  • Penumbra, Inc. (US)
  • Oncotreat SA (Switzerland)
  • Vascular Dynamics, Inc. (US)
  • Shanghai Jahva Medical Co., Ltd. (China)
  • Hangzhou Micro-Tech Co., Ltd. (China)

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Transarterial Chemoembolization Market size was valued at USD 17.81 Billion in 2023 and is poised to grow from USD 18.79 Billion in 2024 to USD 28.83 Billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

Transarterial chemoembolization market is competitive, comprising both well-established vendors as well as new entrants that lead to dynamism in this industry. The major players in the market are engaging in strategies like new product development, collaboration, and consolidation to increase their dominance. Significant contributions to the competitive dynamics include established medical technology companies specializing in interventional oncology (development of advanced catheters, microcatheters, etc.) as well as embolic agents and drug-eluting bead technologies. 'Boston Scientific Corporation (US)', 'Terumo Corporation (Japan)', 'Cook Medical (US)', 'Cardinal Health (US)', 'Becton, Dickinson and Company (US)', 'Guerbet (France)', 'AngioDynamics, Inc. (US)', 'SIRtex Medical Inc. (Australia)', 'Merit Medical Systems Inc. (US)', 'Varian Medical Systems, Inc. (US)', 'Microvena Therapeutics, Inc. (US)', 'RadioMed LLC (US)', 'IGT Laboratories (US)', 'MicroCath, Inc. (US)', 'Spectranetics, Inc. (US)', 'Penumbra, Inc. (US)', 'Oncotreat SA (Switzerland)', 'Vascular Dynamics, Inc. (US)', 'Shanghai Jahva Medical Co., Ltd. (China)', 'Hangzhou Micro-Tech Co., Ltd. (China)'

The increased incidence of liver cancer worldwide with demands for treatment such as the TACE. Moreover, the ongoing improvements in medical techniques continue to improve the accuracy and efficacy of such treatment processes, leading a doctor and a patient to choose them too. Minimally invasive procedures have also become vital drivers for TACE because it helps patients not experience the pain that comes with traditional treatment methods.

The trend towards the individualized treatment of liver cancer. The health care providers are exploring customised TACE based on patients’ characteristic and general health status including that of their tumour types. The trend supports the larger shift toward precision medicine to maximise the patient’s health outcome. Another major trend in the TACE market is technological innovations. This improves the performance of TACE which is ongoing research work to improve its preciseness and effectiveness. The latest developments in embolic agents, as well as, drug-eluting bead technologies and imaging technologies help target cancerous sites so that therapy can be effective with minimal negative impact to other tissues and body organs.

There was a particular region with high demand in terms of the TACE market, called Asia-Pacific. Countries like China have a high prevalence rate of liver cancer. This trend goes along with increased education, better health facilities, as well as increased spending capacity, hence, making Asia Pacific dominate. The fact that some countries like China and India are investing in health care infrastructure and technology also supports the region’s capacity for TACE.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Transcatheter Embolization and Occlusion Devices Market
Buy Now GET FREE SAMPLE
Compounding Chemotherapy Market
Buy Now GET FREE SAMPLE
Pharmaceutical Isolator Market
Buy Now GET FREE SAMPLE
Oncology Ablation Market
Buy Now GET FREE SAMPLE
Transcatheter Devices Market
Buy Now GET FREE SAMPLE
Tumor Ablation Market
Buy Now GET FREE SAMPLE
Venous Thromboembolism Treatment Market
Buy Now GET FREE SAMPLE
Oncology Drugs Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Transarterial Chemoembolization Market

Report ID: SQMIG35I2318

$5,300
BUY NOW GET FREE SAMPLE